Discovery and characterization of exceptionally specific surface oncoprotein LIPI in Ewing Sarcoma
尤文肉瘤中异常特异性表面癌蛋白 LIPI 的发现和表征
基本信息
- 批准号:10721942
- 负责人:
- 金额:$ 18.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-06 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAntibodiesAntibody-drug conjugatesBindingBiological MarkersBiological ProcessBiologyCRISPR/Cas technologyCancer CenterCancer VaccinesCancer cell lineCell LineCell Surface ProteinsCell SurvivalCell TherapyCell physiologyCell surfaceCellsChIP-seqChickensChildChimeric ProteinsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCoupledDataData SetDependenceDevelopmentDiseaseDisease ProgressionDrug TargetingEWS-FLI1 fusion proteinEWSR1 geneEnhancersEnsureEwings sarcomaFLI1 geneFoundationsGene ExpressionGenesGenetic TranscriptionGenotypeGermanyGrowthHumanHydrolaseImmune systemImmunohistochemistryImmunotherapeutic agentImmunotherapyIn VitroInvadedKnock-outLaboratoriesLipaseLipidsMalignant NeoplasmsMapsMediatingMembraneMetastatic Ewing&aposs SarcomaMicrosatellite RepeatsModelingMonoclonal AntibodiesMusNatural Killer CellsNeoplasm MetastasisNormal tissue morphologyOncogenesOncogenicOncoproteinsOutcomePathologyPatientsPatternPennsylvaniaPhenotypePhospholipasePhysiciansPhysiologyPrognostic MarkerProliferatingProteinsProteomicsReagentRecurrenceRegulationResearchRoleScientistSignal PathwaySignal TransductionSpecimenSurfaceSurface AntigensSurvival RateT-LymphocyteThe Cancer Genome AtlasTherapeuticTissue MicroarrayTissuesTranscriptional RegulationTransmembrane DomainTumor AntigensUniversity HospitalsUpstream EnhancerWorkXenograft ModelZebrafishcancer typechimeric antigen receptor T cellsclinically relevantclinically significantdesigndrug discoveryepigenetic silencingextracellulargenetic signaturein vivolysophosphatidic acidmembernew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsoverexpressionprion-likeprofessorprogramsreceptorsarcomasuccesstranscription factortranscriptometranscriptomicstumor growthvaccine-induced antibodiesyoung adult
项目摘要
Project Summary
Children and young adults with metastatic Ewing sarcoma driven by oncogenic fusion transcription factor EWS-
FLI1 continue to have poor outcomes. Immunotherapies using T cells, NK cells, cancer vaccines, and
monoclonal antibodies are being considered for Ewing sarcoma, especially for recurrent patients. The
identification of human tumor-associated antigens (TAAs) recognized by the immune system is crucial for
immunotherapy. Through integration of Ewing sarcoma cell line gene expression, ChIP-seq, and normal and
cancer tissue gene expression from the Genotype-Tissue Expression (GTEx), and the TCGA project, we have
identified LIPI as a highly specific tumor antigen and a potential oncogene that relies on the transcriptional activity
of EWS-FLI1 in Ewing sarcoma. LIPI (Lipase member I (EC:3.1.1.-) is an evolutionarily conserved protein
predicted to poses a transmembrane domain and extracellular lipid hydrolase domain. The biological function of
LIPI is not known but the enzymatic activity of LIPI is expected to produce lysophosphatidic acid (LPA) that
potently affects several biological functions including proliferation, cell survival, and metastasis of tumor cells.
We hypothesize that the LIPI is a unique biomarker and an oncogene that is expressed exclusively in Ewing
sarcoma and is a potential target for cell based therapy. To our knowledge, this proposal represents the first
study evaluating the role of LIPI in cellular physiology and in particular Ewing sarcoma progression and
metastasis. The two specific aims of the projects are:
Specific Aim 1: To elucidate the regulation and role of cell surface LIPI in Ewing sarcoma
Specific Aim 2: To investigate the role of LIPI in Ewing sarcoma growth/metastasis.
Following the successful completion of the proposed aims in this application, we will have evaluated the potential
of LIPI as a Ewing sarcoma specific surface oncoprotein, and will have a long-term impact by establishing the
strong foundation for the development of LIPI-directed immunotherapeutics against Ewing sarcoma.
项目摘要
癌基因融合转录因子EWS-1驱动的儿童和年轻人转移性尤文肉瘤
FLI1的结果仍然很差。使用T细胞、NK细胞、癌症疫苗和
目前正在考虑用单抗治疗尤文肉瘤,特别是复发患者。这个
识别免疫系统识别的人类肿瘤相关抗原(TAA)对于
免疫疗法。通过整合尤文肉瘤细胞系的基因表达,芯片序列,正常和
癌症组织基因表达来自基因类型-组织表达(GTEx)和TCGA项目,我们有
LIPI是一种高度特异的肿瘤抗原和依赖于转录活性的潜在癌基因
EWS-FLI1在尤文肉瘤中的表达。LIPI(Lipase Members I,EC:3.1.1.-)是一种进化保守的蛋白质
预测构成跨膜结构域和细胞外脂水解酶结构域。它的生物学功能
LIPI尚不清楚,但LIPI的酶活性有望产生溶血磷脂酸(LPA),从而
潜在地影响多种生物学功能,包括肿瘤细胞的增殖、细胞存活和转移。
我们假设LIPI是一个独特的生物标志物和癌基因,它只在尤因表达。
肉瘤,是基于细胞的治疗的潜在靶点。据我们所知,这项建议是第一个
评价LIPI在细胞生理学中的作用,特别是尤文肉瘤进展和
转移。这些项目的两个具体目标是:
特异性目标1:阐明细胞表面LIPI在尤文肉瘤中的调节和作用
特异性目的2:探讨LIPI在尤文肉瘤生长/转移中的作用。
在成功完成本申请的拟议目标后,我们将评估其潜力
LIPI作为尤文肉瘤特异性表面癌蛋白,并将通过建立
为开发激光诱导免疫治疗尤文肉瘤奠定了坚实的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Irfan Ahmed Asangani其他文献
Irfan Ahmed Asangani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Irfan Ahmed Asangani', 18)}}的其他基金
Role of MED1 in the AR-dependent transcription in advanced prostate cancer
MED1 在晚期前列腺癌 AR 依赖性转录中的作用
- 批准号:
10356845 - 财政年份:2020
- 资助金额:
$ 18.99万 - 项目类别:
Role of MED1 in the AR-dependent transcription in advanced prostate cancer
MED1 在晚期前列腺癌 AR 依赖性转录中的作用
- 批准号:
10818781 - 财政年份:2020
- 资助金额:
$ 18.99万 - 项目类别:
Role of MED1 in the AR-dependent transcription in advanced prostate cancer
MED1 在晚期前列腺癌 AR 依赖性转录中的作用
- 批准号:
10626720 - 财政年份:2020
- 资助金额:
$ 18.99万 - 项目类别:
Characterization of Epigenetic Targets in Prostate Cancer
前列腺癌表观遗传靶点的表征
- 批准号:
9326820 - 财政年份:2015
- 资助金额:
$ 18.99万 - 项目类别:
Characterization of Epigenetic Targets in Prostate Cancer
前列腺癌表观遗传靶点的表征
- 批准号:
9148273 - 财政年份:2015
- 资助金额:
$ 18.99万 - 项目类别:
Characterization of Epigenetic Targets in Prostate Cancer
前列腺癌表观遗传靶点的表征
- 批准号:
8753640 - 财政年份:2014
- 资助金额:
$ 18.99万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 18.99万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 18.99万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 18.99万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 18.99万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 18.99万 - 项目类别: